author-photo

Miguel Ángel Climent Duran

29

Papers

212

Citations

Citation Trend

Filter By

Papers (19) Sort By

Journal Conference Others

Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Measures to evaluate quality of care in renal cancer: results of a Delphi study in Spain.

2021 Clinical & Translational Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Randomized phase II study of docetaxel (D) + abiraterone acetate (AA) versus D after disease progression to first-line AA in metastatic castration-resistant prostate cancer (mCRPC): ABIDO-SOGUG Trial.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
ECO Experts’ consensus on establishing renal cancer healthcare quality measures in Spain.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
In geriatric evaluation, some iadl (Katz) scale items are more predictive of efficacy and toxicity than ADL (Lawton) scale or Charlson Comorbidity Index in metastasic castration-resistant protate cancer (mCRPC) patients treated with cabazitaxel in a weekly schedule.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (41)
Treatment efficacy of abiraterone (abi), enzalutamide (enza) or cabazitaxel (caba) in metastasic castration-resistant prostate cancer patients (mCRPC) after progression to docetaxel plus androgen deprivation therapy (ADT) in hormone sensible disease.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Phase II trial of cabazitaxel in patients with advanced or metastatic transitional cell carcinoma of the urothelial tract who have progressed within less than 12 months after cisplatin-based chemotherapy: A Spanish Oncology Genitourinary Group (SOGUG) study.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Prospective assessment of circulating endothelial cells (CECs) as pharmacodynamic marker in first line clear cell renal cell carcinoma (CCRCC): The CIRCLES study (SOGUG 2011-01).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)